Hub : Traits :

Medication: Aspirin

19 significantly associated models · 9 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	109098737	110517617	3	1	6.3e-10	4.6e-10	1.0e+00	100	PSRC1
2	4	52683607	53598975	2	1	3.0e-08	9.1e-08	6.8e-02	88	SGCB
3	6	160071844	161571560	1	1	1.5e-08	7.1e-07	7.9e-06	19	SLC22A3
4	9	21303958	22819407	2	1	7.4e-11	7.4e-18	1.7e-08	57	CDKN2B
5	15	90730363	92135418	1	1	1.9e-08	1.0e-06	8.7e-01	100	FES

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
LDL Cholesterol	98.73	1	1	2.2	0.00	1.0e+00	PSRC1
High cholesterol (Self-reported)	47.87	3	2	4.4	0.00	1.0e+00	FES PSRC1 SLC22A3
Medication: Cholesterol lowering	42.87	5	2	4.4	0.94	1.9e-02	CDKN2B FES PSRC1 SGCB SLC22A3
Angina (self-reported)	35.04	4	4	8.9	0.99	9.2e-03	CDKN2B FES PSRC1 SLC22A3
Illnesses of father: Heart disease	35.00	4	4	8.9	1.00	2.8e-03	CDKN2B FES PSRC1 SLC22A3
Angina	33.31	4	4	8.9	0.99	1.4e-02	CDKN2B FES PSRC1 SLC22A3
Medication: Simvastatin	31.22	5	2	4.4	0.95	1.2e-02	CDKN2B FES PSRC1 SGCB SLC22A3
Coronary Artery Disease (CAD)	29.52	3	2	4.4	0.00	1.0e+00	CDKN2B PSRC1 SLC22A3
Medication: Atorvastatin	29.22	3	2	4.4	0.00	1.0e+00	CDKN2B PSRC1 SLC22A3
Cholesterol lowering medication	26.97	4	2	4.4	0.97	2.5e-02	CDKN2B PSRC1 SGCB SLC22A3
Medication: Aspirin	26.64	5	5	11.1	1.00	5.3e-08	CDKN2B FES PSRC1 SGCB SLC22A3
Heart attack/myocardial infarction (self-reported)	26.24	4	4	8.9	1.00	3.1e-03	CDKN2B FES PSRC1 SLC22A3
Heart attack	26.03	4	4	8.9	1.00	2.8e-03	CDKN2B FES PSRC1 SLC22A3
Medication for cholesterol, blood pressure or diabetes	21.73	2	2	4.4	0.00	1.0e+00	FES PSRC1
Cardiovascular Disease	16.80	4	2	4.4	0.99	1.0e-02	FES PSRC1 SGCB SLC22A3
Vascular/heart problems diagnosed by doctor	16.45	3	1	2.2	0.00	1.0e+00	CDKN2B FES SLC22A3
Illnesses of father: None of the above (group 1)	16.37	3	2	4.4	0.00	1.0e+00	CDKN2B FES SLC22A3
Heart disease (mother)	15.18	3	2	4.4	0.00	1.0e+00	CDKN2B FES SLC22A3
High blood pressure (mother)	13.86	1	1	2.2	0.00	1.0e+00	FES
Hypertension (Self-reported)	13.67	2	1	2.2	0.00	1.0e+00	FES SLC22A3
Medication: Atenolol	13.66	3	1	2.2	0.00	1.0e+00	CDKN2B FES PSRC1
Systolic Blood Pressure	13.22	3	1	2.2	0.00	1.0e+00	FES SGCB SLC22A3
High blood pressure	13.10	1	1	2.2	0.00	1.0e+00	FES
Medication for cholesterol	12.63	3	1	2.2	0.00	1.0e+00	FES PSRC1 SLC22A3
Heart disease (siblings)	12.48	4	0	0.0	0.97	3.1e-02	CDKN2B FES PSRC1 SLC22A3
Medication: Blood pressure	12.20	3	1	2.2	0.00	1.0e+00	FES SGCB SLC22A3
Medication: Blood pressure	12.10	1	1	2.2	0.00	1.0e+00	FES
Father's age at death	12.06	4	1	2.2	-1.00	5.0e-03	CDKN2B FES PSRC1 SGCB
Systolic blood pressure, automated reading	11.90	2	1	2.2	0.00	1.0e+00	FES SGCB
Eye problems/disorders: Glaucoma	11.87	1	1	2.2	0.00	1.0e+00	CDKN2B
Illnesses of mother	9.85	2	1	2.2	0.00	1.0e+00	CDKN2B FES
Diastolic blood pressure, automated reading	9.70	2	1	2.2	0.00	1.0e+00	CDKN2B FES
Illnesses of father: High blood pressure	9.69	1	1	2.2	0.00	1.0e+00	FES
Glaucoma (self-reported)	8.60	1	1	2.2	0.00	1.0e+00	CDKN2B
High blood pressure (siblings)	8.22	2	1	2.2	0.00	1.0e+00	FES SGCB
Medication: Ramipril	7.78	2	0	0.0	0.00	1.0e+00	FES SLC22A3
Illnesses of siblings	7.20	2	1	2.2	0.00	1.0e+00	FES SGCB
Birth weight of first child	7.17	1	1	2.2	0.00	1.0e+00	FES
Number of treatments/medications taken	6.98	3	1	2.2	0.00	1.0e+00	FES PSRC1 SGCB
Medication: Amlodipine	6.71	1	1	2.2	0.00	1.0e+00	FES
Bipolar Disorder or Schizophrenia	5.80	1	1	2.2	0.00	1.0e+00	FES
Schizophrenia (2018)	5.69	1	1	2.2	0.00	1.0e+00	FES
Medication: Metformin	5.45	2	0	0.0	0.00	1.0e+00	CDKN2B SGCB
Schizophrenia (2014)	5.26	1	1	2.2	0.00	1.0e+00	FES
Medication: Bendroflumethiazide	4.93	1	1	2.2	0.00	1.0e+00	FES
Pulse wave peak to peak time	4.53	2	0	0.0	0.00	1.0e+00	CDKN2B FES
Type 2 Diabetes (T2D) (2012)	4.47	1	0	0.0	0.00	1.0e+00	CDKN2B
Chest pain or discomfort	4.36	1	0	0.0	0.00	1.0e+00	CDKN2B
Type 2 Diabetes (T2D) (2018)	4.33	3	0	0.0	0.00	1.0e+00	CDKN2B SGCB SLC22A3
Lung cancer (father)	4.32	1	0	0.0	0.00	1.0e+00	FES
Pulse wave Arterial Stiffness index	4.26	2	0	0.0	0.00	1.0e+00	CDKN2B FES
Number of self-reported non-cancer illnesses	4.24	1	0	0.0	0.00	1.0e+00	SLC22A3
Diabetes diagnosed by doctor	4.20	2	0	0.0	0.00	1.0e+00	SGCB SLC22A3
Birth weight	4.19	1	1	2.2	0.00	1.0e+00	FES
Basal cell carcinoma (self-reported)	4.01	1	0	0.0	0.00	1.0e+00	CDKN2B
Breast Cancer	3.83	2	0	0.0	0.00	1.0e+00	CDKN2B FES
Diabetes (self-reported)	3.76	1	0	0.0	0.00	1.0e+00	SGCB
Supplements: Fish oil (including cod liver oil)	3.63	2	0	0.0	0.00	1.0e+00	FES SLC22A3
Sensitivity / hurt feelings	3.56	1	1	2.2	0.00	1.0e+00	FES
Breastfed as a baby	3.50	1	0	0.0	0.00	1.0e+00	FES
Waist Hip Ratio (WHR)	3.45	1	1	2.2	0.00	1.0e+00	SLC22A3
Smoking Status	3.37	2	0	0.0	0.00	1.0e+00	FES PSRC1
Mineral and other dietary supplements	3.30	2	0	0.0	0.00	1.0e+00	FES SLC22A3
Number of incorrect matches in round	3.27	1	0	0.0	0.00	1.0e+00	FES
Long-standing illness, disability or infirmity	3.25	1	0	0.0	0.00	1.0e+00	CDKN2B
Body Mass Index (BMI) (2010)	3.20	1	0	0.0	0.00	1.0e+00	SGCB
Hearing difficulty/problems: Yes	3.18	2	0	0.0	0.00	1.0e+00	PSRC1 SGCB
Medication for pain relief, constipation, heartburn	3.12	1	0	0.0	0.00	1.0e+00	PSRC1
Headache pain in last month	3.09	1	0	0.0	0.00	1.0e+00	FES
Medication: Lisinopril	3.06	1	0	0.0	0.00	1.0e+00	FES
HDL Cholesterol	2.96	1	0	0.0	0.00	1.0e+00	PSRC1
Average weekly red wine intake	2.96	1	0	0.0	0.00	1.0e+00	SLC22A3
Alcohol usually taken with meals	2.95	1	0	0.0	0.00	1.0e+00	FES
Medication: Ibuprofen	2.92	1	0	0.0	0.00	1.0e+00	SLC22A3
Risk taking	2.90	1	0	0.0	0.00	1.0e+00	FES
Trunk fat mass	2.86	2	1	2.2	0.00	1.0e+00	SGCB SLC22A3
Prospective memory result	2.84	1	0	0.0	0.00	1.0e+00	SGCB
Whole body fat mass	2.71	2	1	2.2	0.00	1.0e+00	SGCB SLC22A3
Osteoporosis (self-reported)	2.61	1	0	0.0	0.00	1.0e+00	SLC22A3
Medication: Gliclazide	2.61	1	0	0.0	0.00	1.0e+00	CDKN2B
Leg predicted mass (right)	2.60	4	0	0.0	-0.62	3.8e-01	FES PSRC1 SGCB SLC22A3
Leg fat-free mass (right)	2.58	4	0	0.0	-0.61	3.9e-01	FES PSRC1 SGCB SLC22A3
Leg predicted mass (left)	2.55	4	0	0.0	-0.57	4.3e-01	FES PSRC1 SGCB SLC22A3
Weight	2.54	2	1	2.2	0.00	1.0e+00	SGCB SLC22A3
Arm fat mass (right)	2.54	2	0	0.0	0.00	1.0e+00	SGCB SLC22A3
Respiratory disease	2.52	1	0	0.0	0.00	1.0e+00	FES
Leg fat-free mass (left)	2.52	4	0	0.0	-0.57	4.3e-01	FES PSRC1 SGCB SLC22A3
Alcohol intake versus 10 years previously	2.52	1	0	0.0	0.00	1.0e+00	SGCB
Breast cancer (self-reported)	2.51	1	0	0.0	0.00	1.0e+00	CDKN2B
Handedness (chirality/laterality): Left-handed	2.49	1	0	0.0	0.00	1.0e+00	FES
Arm fat mass (left)	2.49	2	0	0.0	0.00	1.0e+00	SGCB SLC22A3
Basal metabolic rate	2.49	4	0	0.0	-0.52	4.8e-01	FES PSRC1 SGCB SLC22A3
Trunk fat-free mass	2.48	4	1	2.2	-0.58	4.2e-01	FES PSRC1 SGCB SLC22A3
Trunk predicted mass	2.47	4	1	2.2	-0.57	4.3e-01	FES PSRC1 SGCB SLC22A3
Whole body fat-free mass	2.47	4	0	0.0	-0.58	4.2e-01	FES PSRC1 SGCB SLC22A3
Trunk fat percentage	2.46	2	0	0.0	0.00	1.0e+00	SGCB SLC22A3
Bipolar Disorder (2018)	2.42	1	0	0.0	0.00	1.0e+00	FES
Arm predicted mass (right)	2.41	3	0	0.0	0.00	1.0e+00	PSRC1 SGCB SLC22A3
Whole body water mass	2.41	4	0	0.0	-0.59	4.1e-01	FES PSRC1 SGCB SLC22A3
Age started oral contraceptive pill	2.37	1	0	0.0	0.00	1.0e+00	FES
Arm predicted mass (left)	2.36	3	0	0.0	0.00	1.0e+00	PSRC1 SGCB SLC22A3
Hip circumference	2.34	2	1	2.2	0.00	1.0e+00	SGCB SLC22A3
Current tobacco smoking	2.31	1	0	0.0	0.00	1.0e+00	FES
Allergy	2.29	1	0	0.0	0.00	1.0e+00	FES
Blood White Count	2.24	4	1	2.2	0.62	3.8e-01	CDKN2B FES PSRC1 SGCB
Arm fat-free mass (right)	2.24	3	0	0.0	0.00	1.0e+00	PSRC1 SGCB SLC22A3
Medication: Ibuprofen (e.g. Nurofen)	2.21	1	0	0.0	0.00	1.0e+00	SLC22A3
Arm fat-free mass (left)	2.18	3	0	0.0	0.00	1.0e+00	PSRC1 SGCB SLC22A3
Arm fat percentage (right)	2.16	2	0	0.0	0.00	1.0e+00	SGCB SLC22A3
Body fat percentage	2.15	2	0	0.0	0.00	1.0e+00	SGCB SLC22A3
Allergy or Eczema	2.10	2	0	0.0	0.00	1.0e+00	FES SLC22A3
Hair/balding pattern: Pattern 4	2.08	1	0	0.0	0.00	1.0e+00	FES
Leg fat mass (right)	2.08	2	0	0.0	0.00	1.0e+00	SGCB SLC22A3
Mean time to correctly identify matches	2.07	1	0	0.0	0.00	1.0e+00	FES
Comparative height size at age 10	2.07	4	0	0.0	-0.67	3.3e-01	FES PSRC1 SGCB SLC22A3
Severe depression (siblings)	2.04	1	0	0.0	0.00	1.0e+00	FES
Impedance of leg (right)	2.04	1	1	2.2	0.00	1.0e+00	FES
Past tobacco smoking	2.03	1	0	0.0	0.00	1.0e+00	FES
Leg fat mass (left)	2.03	2	0	0.0	0.00	1.0e+00	SGCB SLC22A3
Hayfever, allergic rhinitis or eczema	2.01	1	0	0.0	0.00	1.0e+00	FES
Arm fat percentage (left)	1.97	2	0	0.0	0.00	1.0e+00	SGCB SLC22A3
Hand grip strength (left)	1.95	1	0	0.0	0.00	1.0e+00	FES
Impedance of leg (left)	1.89	1	1	2.2	0.00	1.0e+00	FES
BMI	1.86	2	0	0.0	0.00	1.0e+00	SGCB SLC22A3
Ever smoked	1.85	1	0	0.0	0.00	1.0e+00	FES
Ovarian Cancer	1.81	1	0	0.0	0.00	1.0e+00	FES
Mouth/teeth dental problems	1.76	1	0	0.0	0.00	1.0e+00	CDKN2B
Chronotype (morning person)	1.69	1	0	0.0	0.00	1.0e+00	SGCB
Height	1.68	4	4	8.9	-0.64	3.6e-01	FES PSRC1 SGCB SLC22A3
Waist circumference	1.66	1	0	0.0	0.00	1.0e+00	SGCB
Crohns Disease (2012)	1.64	1	0	0.0	0.00	1.0e+00	FES
Number of live births	1.60	1	0	0.0	0.00	1.0e+00	FES
Asthma (self-reported)	1.50	1	0	0.0	0.00	1.0e+00	FES
Asthma	1.49	1	0	0.0	0.00	1.0e+00	FES
Standing height	1.45	3	1	2.2	0.00	1.0e+00	PSRC1 SGCB SLC22A3
Crohns Disease (2017)	1.33	1	0	0.0	0.00	1.0e+00	FES
Leg fat percentage (right)	1.33	1	0	0.0	0.00	1.0e+00	SGCB
Neuroticism (Nagel 2018)	1.27	1	0	0.0	0.00	1.0e+00	FES
Lung FEV1/FVC ratio	1.27	1	1	2.2	0.00	1.0e+00	PSRC1
Body mass index (BMI)	1.27	1	0	0.0	0.00	1.0e+00	SGCB
Impedance of whole body	1.25	2	0	0.0	0.00	1.0e+00	FES PSRC1
Leg fat percentage (left)	1.15	1	0	0.0	0.00	1.0e+00	SGCB
Irritable Bowel Disease (IBD)	1.12	1	0	0.0	0.00	1.0e+00	FES
Blood Platelet Count	1.08	3	0	0.0	0.00	1.0e+00	CDKN2B SGCB SLC22A3
Sitting height	1.08	2	0	0.0	0.00	1.0e+00	FES SLC22A3
Impedance of arm (right)	1.06	2	0	0.0	0.00	1.0e+00	CDKN2B PSRC1
Neuroticism	1.03	1	0	0.0	0.00	1.0e+00	FES
Impedance of arm (left)	0.87	1	0	0.0	0.00	1.0e+00	PSRC1
Hair Pigment	0.82	2	2	4.4	0.00	1.0e+00	CDKN2B FES
Heel T-Score	0.58	1	0	0.0	0.00	1.0e+00	PSRC1
Blood Red Count	0.50	2	0	0.0	0.00	1.0e+00	CDKN2B FES

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Spleen	0	0.000	1.5
GTEx	Adrenal Gland	0	0.000	1.4
GTEx	Artery Aorta	0	0.000	1.4
GTEx	Artery Tibial	0	0.000	1.4
GTEx	Brain Cortex	0	0.000	1.4
GTEx	Brain Frontal Cortex BA9	0	0.000	1.4
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.4
GTEx	Colon Transverse	0	0.000	1.4
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.4
GTEx	Heart Atrial Appendage	0	0.000	1.4
GTEx	Liver	1	0.139	1.4
GTEx	Muscle Skeletal	1	0.035	1.4
GTEx	Ovary	0	0.000	1.4
GTEx	Pancreas	0	0.000	1.4
GTEx	Skin Not Sun Exposed Suprapubic	0	0.000	1.4
GTEx	Small Intestine Terminal Ileum	0	0.000	1.4
GTEx	Stomach	0	0.000	1.4
GTEx	Thyroid	0	0.000	1.4
GTEx	Vagina	0	0.000	1.4
GTEx	Whole Blood	1	0.050	1.4
The Cancer Genome Atlas	Colon Adenocarcinoma	1	0.048	1.4
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.4
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.4
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.4
GTEx	Adipose Subcutaneous	0	0.000	1.3
GTEx	Adipose Visceral Omentum	0	0.000	1.3
GTEx	Artery Coronary	0	0.000	1.3
GTEx	Brain Caudate basal ganglia	0	0.000	1.3
GTEx	Brain Cerebellar Hemisphere	0	0.000	1.3
GTEx	Brain Cerebellum	0	0.000	1.3
GTEx	Brain Hippocampus	0	0.000	1.3
GTEx	Brain Hypothalamus	0	0.000	1.3
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.3
GTEx	Brain Putamen basal ganglia	0	0.000	1.3
GTEx	Breast Mammary Tissue	1	0.051	1.3
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.3
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.3
GTEx	Cells Transformed fibroblasts	1	0.024	1.3
GTEx	Colon Sigmoid	0	0.000	1.3
GTEx	Esophagus Mucosa	1	0.030	1.3
GTEx	Esophagus Muscularis	0	0.000	1.3
GTEx	Heart Left Ventricle	0	0.000	1.3
GTEx	Lung	0	0.000	1.3
GTEx	Nerve Tibial	0	0.000	1.3
GTEx	Pituitary	0	0.000	1.3
GTEx	Prostate	0	0.000	1.3
GTEx	Skin Sun Exposed Lower leg	0	0.000	1.3
GTEx	Testis	1	0.032	1.3
GTEx	Uterus	0	0.000	1.3
METSIM	Adipose	0	0.000	1.3
NTR	Blood	0	0.000	1.3
ROSMAP	Brain Pre-frontal Cortex	1	0.023	1.3
YFS	Blood	0	0.000	1.3
CommonMind	Brain Pre-frontal Cortex	4	0.074	1.3
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	1	0.023	1.3
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Glioblastoma Multiforme	0	0.000	1.3
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	1	0.049	1.3
The Cancer Genome Atlas	Brain Lower Grade Glioma	0	0.000	1.3
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.181	1.3
The Cancer Genome Atlas	Lung Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.3
The Cancer Genome Atlas	Prostate Adenocarcinoma	1	0.022	1.3
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.3
The Cancer Genome Atlas	Stomach Adenocarcinoma	1	0.059	1.3
The Cancer Genome Atlas	Testicular Germ Cell Tumors	0	0.000	1.3
The Cancer Genome Atlas	Thyroid Carcinoma	0	0.000	1.3